How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hyperparathyroidism-secondary-to-chronic-renal-failure-with-dialysis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Sensipar	CINACALCET	Amgen	Calcium-sensing Receptor Agonist	Extracellular calcium-sensing receptor	2004-01-01
Hectorol	DOXERCALCIFEROL	Sanofi	Vitamin D2 Analog [EPC]	Vitamin D3 receptor	1999-01-01
Drisdol	ERGOCALCIFEROL	Esjay Pharma	Provitamin D2 Compound [EPC]	25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	1941-01-01
Calciferol	Calciferol	Department of Medical Services Ministry of Public Health of Thailand		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amgen · 1 drug in Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis
Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis
Esjay Pharma · 1 drug in Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis
Sanofi · 1 drug in Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis:

Cite this brief

Drug Landscape (2026). Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hyperparathyroidism-secondary-to-chronic-renal-failure-with-dialysis. Accessed 2026-06-09.

Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing